ReviewJournal of human hypertension2015
An update on the pharmacogenetics of treating hypertension.
Review in Journal of human hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.Hypertension (Dallas, Tex. : 1979) · 2017Pooled it
- Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.Clinical and translational science · 2019Trial
- Exploring Pharmacogenetic Testing for Hypertension Management in China.China CDC weekly · 2023Article
- Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.British journal of clinical pharmacology · 2023Article
- Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021Review
- Genetics of macrovascular complications in type 2 diabetes.World journal of diabetes · 2021Review
- Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions.Frontiers in pharmacology · 2018Article
- Applying Systems Biology Methodology To Identify Genetic Factors Possibly Associated with Recovery after Traumatic Brain Injury.Journal of neurotrauma · 2017Article
- Article
- Can we predict the blood pressure response to renal denervation?Autonomic neuroscience : basic & clinical · 2017Review
- Experts Provide a Glimpse of the New Post-SPRINT Era of Hypertension.P & T : a peer-reviewed journal for formulary management · 2017Article
- Personalized Management of Cardiovascular Disorders.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017Review
- The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study.Clinical drug investigation · 2016Observational
- Recent Advances in Application of Pharmacogenomics for Biotherapeutics.The AAPS journal · 2016Review
- Personalized Therapy of Hypertension: the Past and the Future.Current hypertension reports · 2016Review
- Association of methylenetetrahydrofolate reductase gene (C677T) with the risk of hypertension in Morocco.BMC research notes · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a leading cause of cardiovascular mortality, but only one third of patients achieve blood pressure goals despite antihypertensive therapy. Genetic polymorphisms may partially account for the interindividual variability and abnormal response to antihypertensive drugs. Candidate gene and genome-wide approaches have identified common genetic variants associated with response to antihypertensive drugs. However, there is no currently available pharmacogenetic test to guide hypertension treatment in clinical practice. In this review, we aimed to summarize the recent findings on pharmacogenetics of the most commonly used antihypertensive drugs in clinical practice, including diuretics, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta-blockers and calcium channel blockers. Notably, only a small percentage of the genetic variability on response to antihypertensive drugs has been explained, and the vast majority of the genetic variants associated with antihypertensives efficacy and toxicity remains to be identified. Despite some genetic variants with evidence of association with the variable response related to these most commonly used antihypertensive drug classes, further replication is needed to confirm these associations in different populations. Further studies on epigenetics and regulatory pathways involved in the responsiveness to antihypertensive drugs might provide a deeper understanding of the physiology of hypertension, which may favor the identification of new targets for hypertension treatment and genetic predictors of antihypertensive response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.